Empagliflozin and Insulin degludec Subcutaneous
Determining the interaction of Empagliflozin and Insulin degludec Subcutaneous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Empagliflozin may help control blood glucose levels, which may lead to a reduction in your dosage requirement of insulin degludec or any other diabetic medications you are receiving. Your blood glucose should be closely monitored so that medications may be adjusted accordingly by your doctor. Let your doctor know if you experience hypoglycemia, or low blood sugar. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Likewise, if empagliflozin is discontinued, your blood glucose may increase and hyperglycemia may occur, which may require readjustment of your medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.
MANAGEMENT: A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.
- "Product Information. Steglatro (ertugliflozin)." Merck & Company Inc, Whitehouse Station, NJ.
- "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: empagliflozin
Brand name: Jardiance
Synonyms: n.a.
Generic Name: insulin degludec
Brand name: Tresiba, Tresiba FlexTouch
Synonyms: Insulin degludec, Insulin Degludec
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Empagliflozin-Insulin detemir
- Empagliflozin-Insulin Detemir (Cartridges and Prefilled Syringes)
- Empagliflozin-Insulin Detemir (Vials)
- Empagliflozin-Insulin detemir Subcutaneous
- Empagliflozin-Insulin glargine
- Empagliflozin-Insulin Glargine (U-100) Cartridge Systems and Pens
- Insulin degludec Subcutaneous-Empagliflozin and linagliptin
- Insulin degludec Subcutaneous-Empagliflozin and metformin
- Insulin degludec Subcutaneous-Empagliflozin and Metformin Extended-Release Tablets
- Insulin degludec Subcutaneous-Empagliflozin and Metformin Tablets
- Insulin degludec Subcutaneous-Empliciti
- Insulin degludec Subcutaneous-Emsam